Cell line · CVCL_0623
MDA-MB-436
Cancer cell line, Homo sapiens. Invasive breast carcinoma of no special type. 100 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. MDA-MB-436. Cell lines, record CVCL_0623. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_0623
On this page
Cell line
As Cellosaurus gives it.
- Name
- MDA-MB-436
- Accession
- CVCL_0623
- RRID
- RRID:CVCL_0623
- Synonyms
- MDA_MB_436, MDA MB 436, MDA-Mb-436, MDA-MB436, MDAMB436, MDA-436, MDA436, MB436, MD Anderson-Metastatic Breast-436
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 43Y
- Category
- Cancer cell line
- Diseases
- Invasive breast carcinoma of no special type (NCIt C4194)
- Derived from
- Pleural effusion (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers100
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| ZBTB1 Regulates Glycolysis and Chemotherapy Resistance Through Interacting with c-Myc in Triple Negative Breast Cancer. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lysyl oxidase inhibition disrupts mitochondrial homeostasis to create vulnerability to ferroptosis in TNBC. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ENO2 sustains cancer stemness and metastatic competence through a phosphoenolpyruvate-dependent metabolic axis in triple-negative breast cancer. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Repurposing Artesunate to Combat Progression and Metastasis via Targeting Circulating Tumor Cells. | Oncol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CerS2 Is a Druggable Target in Triple-Negative Breast Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. | Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PM534, a Novel Colchicine Site Tubulin Inhibitor with Broad-Spectrum and Resistance-Overcoming Antitumor Activity. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 100
See all 100 papersRelatives4
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | HyCyte MDA-MB-436 KO-hARTN | CVCL_F1RT | Cell lines | |
| Derived from it | HyCyte MDA-MB-436 stable cell line for hBRCA1 overexpression | CVCL_F4VK | Cell lines | |
| Derived from it | MDA-MB-436/GFP | CVCL_JY98 | Cell lines | |
| Derived from it | MDA-MB-436/RFP | CVCL_JY99 | Cell lines |
Cell banks6
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | HTB-130 | ATCC | |
| CLS | 300278 | CLS | |
| Hysigen | TCH-C251 | Hysigen | |
| ICLC | HTL11005 | ICLC | |
| IZSLER | BS TCL 246 | Cellosaurus | |
| NCI-DCTD | MDA-MB-436 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0623
GET https://conductscience.org/api/cell-lines/v1/CVCL_0623/papers?page=2